Abstract
The chronic lung inflammatory activity and carcinogenicity of nickel compounds have been well documented by previous studies from epidemiology both in vitro and in vivo. However, the molecular mechanism involved in nickelinduced chronic lung inflammation is much less understood. The current study demonstrates that exposure of human bronchial epithelial cells (Beas-2B) to nickel compounds results in the induction of the inflammatory cytokine tumor necrosis factor-α (TNF-α) and transactivation of nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB), and activator protein-1 (AP-1). Further studies show that neither overexpression of IKKβ-KM, a kinase inactive mutant of IKKβ, nor the ectopic expression of a dominant negative mutant of NFAT could inhibit the TNF-α induction by nickel exposure. Overexpression of TAM67, a dominant-negative mutant of c-Jun, dramatically reduced the TNF-α induction, suggesting that AP-1 is a mediator of TNF-α induction in nickel responses. Our results show that ERKs are AP-1 upstream kinases responsible for TNF-α induction by nickel exposure; although JNKs, ERKs, and p38K were all activated in the Beas-2B cells exposed to nickel compounds. Our results demonstrate that inflammatory TNF-α could be induced by nickel exposure in Beas-2B cells specifically through an ERKs/AP-1-dependent pathway.
Keywords: Kinase, TNF-α, transcriptional factor, nickel, lung
Current Cancer Drug Targets
Title: TNF-α Induction by Nickel Compounds is Specific Through ERKs/AP-1- Dependent Pathway in Human Bronchial Epithelial Cells
Volume: 9 Issue: 1
Author(s): Jin Ding, Yi Huang, Beifang Ning, Wenfeng Gong, Jingxia Li, Hongyang Wang, Chang-Yan Chen and Chuanshu Huang
Affiliation:
Keywords: Kinase, TNF-α, transcriptional factor, nickel, lung
Abstract: The chronic lung inflammatory activity and carcinogenicity of nickel compounds have been well documented by previous studies from epidemiology both in vitro and in vivo. However, the molecular mechanism involved in nickelinduced chronic lung inflammation is much less understood. The current study demonstrates that exposure of human bronchial epithelial cells (Beas-2B) to nickel compounds results in the induction of the inflammatory cytokine tumor necrosis factor-α (TNF-α) and transactivation of nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB), and activator protein-1 (AP-1). Further studies show that neither overexpression of IKKβ-KM, a kinase inactive mutant of IKKβ, nor the ectopic expression of a dominant negative mutant of NFAT could inhibit the TNF-α induction by nickel exposure. Overexpression of TAM67, a dominant-negative mutant of c-Jun, dramatically reduced the TNF-α induction, suggesting that AP-1 is a mediator of TNF-α induction in nickel responses. Our results show that ERKs are AP-1 upstream kinases responsible for TNF-α induction by nickel exposure; although JNKs, ERKs, and p38K were all activated in the Beas-2B cells exposed to nickel compounds. Our results demonstrate that inflammatory TNF-α could be induced by nickel exposure in Beas-2B cells specifically through an ERKs/AP-1-dependent pathway.
Export Options
About this article
Cite this article as:
Ding Jin, Huang Yi, Ning Beifang, Gong Wenfeng, Li Jingxia, Wang Hongyang, Chen Chang-Yan and Huang Chuanshu, TNF-α Induction by Nickel Compounds is Specific Through ERKs/AP-1- Dependent Pathway in Human Bronchial Epithelial Cells, Current Cancer Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/156800909787313995
DOI https://dx.doi.org/10.2174/156800909787313995 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Ultraviolet B Regulation of Transcription Factor Families: Roles of Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1) in UVB-Induced Skin Carcinogenesis
Current Cancer Drug Targets PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Molecular Testing and Personalized Treatment of Lung Cancer
Current Molecular Pharmacology Advances and Challenges in the Synthesis of Highly Oxidised Natural Phenols with Antiviral, Antioxidant and Cytotoxic Activities
Current Medicinal Chemistry Recent Advances in Combined Modality Therapy for Locally Advanced Head and Neck Cancer
Current Cancer Drug Targets Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Immunotherapy in Bladder Cancer
Current Molecular Pharmacology α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Dehydrocostus Lactone Induces Apoptosis and Cell Cycle Arrest through Regulation of JAK2/STAT3/PLK1 Signaling Pathway in Human Esophageal Squamous Cell Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Bladder Cancer: Update on Risk Factors, Molecular and Ultrastructural Patterns
Current Medicinal Chemistry Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Effects of Curcumin on Squamous Cell Carcinoma of Tongue: An In Vitro Study
Current Topics in Medicinal Chemistry Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine